A single combined-drug inhaler used as needed protects adults with mild asthma from worsening illness and hospital stays, a recent commentary on Cochrane systematic review data reports. But long-term ...

Please provide your email address to receive an email when new articles are posted on . Use of a single inhaler with albuterol and corticosteroids as needed reduced exacerbations by 26%. As-needed ...

Not all asthma is created equal, nor will all therapies work for all patients. With continued innovations in asthma treatments offering new, improved options for patients, we are more prepared than ...

CHICAGO -- A fixed-dose inhaler combining an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta agonist (ICS/LAMA/LABA) improved lung function and reduced exacerbations in ...

Three studies have shown that doubling the dose of ICS is not effective for treatment of exacerbations. Several studies have shown benefit from high dose ICS (2400-4000ìg beclomethasone equivalent) ...

ATS 2024, San Diego – Only 14.5 percent of adult patients with moderate or severe asthma are prescribed the recommended SMART combination inhaler regimen and over 40 percent of academic pulmonary and ...

Please provide your email address to receive an email when new articles are posted on . Global Initiative for Asthma (GINA) guidelines recommend single maintenance and reliever therapy (SMART) for ...

Changing patients from an inhaled corticosteroid (ICS)/long-acting β agonist (LABA) inhaler and long-acting muscarinic agonist (LAMA) inhaler to a LAMA/LABA inhaler and a separate ICS inhaler did not ...

Low number of patients treated based on the Single Maintenance and Reliever Therapy (SMART) guideline. HealthDay News — Only 14.5% of adult patients with moderate or severe asthma are prescribed the ...

AstraZeneca already has its aging two-drug inhaler Symbicort as a maintenance treatment for asthma. Now, with a pair of trial wins, the company looks on track to have a novel doublet for controlling ...